1. Home
  2. MCHX vs GANX Comparison

MCHX vs GANX Comparison

Compare MCHX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCHX
  • GANX
  • Stock Information
  • Founded
  • MCHX 2003
  • GANX 2017
  • Country
  • MCHX United States
  • GANX United States
  • Employees
  • MCHX N/A
  • GANX N/A
  • Industry
  • MCHX Business Services
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MCHX Consumer Discretionary
  • GANX Health Care
  • Exchange
  • MCHX Nasdaq
  • GANX Nasdaq
  • Market Cap
  • MCHX 84.3M
  • GANX 79.8M
  • IPO Year
  • MCHX 2004
  • GANX 2021
  • Fundamental
  • Price
  • MCHX $1.83
  • GANX $1.76
  • Analyst Decision
  • MCHX
  • GANX Strong Buy
  • Analyst Count
  • MCHX 0
  • GANX 6
  • Target Price
  • MCHX N/A
  • GANX $8.00
  • AVG Volume (30 Days)
  • MCHX 37.3K
  • GANX 927.8K
  • Earning Date
  • MCHX 11-14-2025
  • GANX 11-12-2025
  • Dividend Yield
  • MCHX N/A
  • GANX N/A
  • EPS Growth
  • MCHX N/A
  • GANX N/A
  • EPS
  • MCHX N/A
  • GANX N/A
  • Revenue
  • MCHX $47,534,000.00
  • GANX N/A
  • Revenue This Year
  • MCHX N/A
  • GANX N/A
  • Revenue Next Year
  • MCHX $7.56
  • GANX N/A
  • P/E Ratio
  • MCHX N/A
  • GANX N/A
  • Revenue Growth
  • MCHX N/A
  • GANX N/A
  • 52 Week Low
  • MCHX $1.26
  • GANX $1.41
  • 52 Week High
  • MCHX $2.40
  • GANX $2.81
  • Technical
  • Relative Strength Index (RSI)
  • MCHX 39.44
  • GANX 43.50
  • Support Level
  • MCHX $1.73
  • GANX $1.74
  • Resistance Level
  • MCHX $1.89
  • GANX $2.08
  • Average True Range (ATR)
  • MCHX 0.09
  • GANX 0.15
  • MACD
  • MCHX -0.00
  • GANX -0.03
  • Stochastic Oscillator
  • MCHX 12.92
  • GANX 7.89

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: